In the present study, we targeted MYCN pharmacologically in RB cells using two classes of small molecule inhibitors: selective bromodomain inhibitors and inhibitors of MYC-MAX interaction, and by shRNA mediated knockdown approach. The gene discussed is MAX; the disease is retinoblastoma.